La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Mirum Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Mirum Pharmaceuticals..

Mirum Pharmaceuticals (NASDAQ:MIRM) Azioni, Catena delle Opzioni

MIRUM PHARMACEUTICALS INC

Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals Inc

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) affirms FY2025 GAAP EPS guidance from $5.34-$5.80 to $5.34-$5.80 vs $5.81 analyst estimate..

News

Guidance

CRH Affirms FY2025 GAAP EPS Guidance of $5.34-$5.80 vs $5.81 Est

WIIM

PLTR

Palantir Technologies shares are trading lower. The company reported Q1 financial results.

CRH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRH#NYSE">CRH</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.07) by 114.29 percent. This is a 193.75 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $6.76 billion which beat the analyst consensus estimate of $6.75 billion by 0.03 percent. This is a 3.41 percent increase over sales of $6.53 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

CRH Q1 EPS $(0.15) Misses $(0.07) Estimate, Sales $6.76B Beat $6.75B Estimate

Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.02 by 600 percent. This is a 71.43 percent decrease over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $37.42 billion which beat the analyst consensus estimate of $36.20 billion by 3.36 percent. This is a 6.19 percent decrease over sales of $39.89 billion the same period last year.

Ford Motor Q1 Adj. EPS $0.14 Beats $0.02 Estimate, Sales $37.42B Beat $36.20B Estimate

Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) affirms FY2025 FFO guidance from $3.85-$4.05 to $3.85-$4.05 vs $4.00 analyst estimate..

Kilroy Realty Affirms FY2025 FFO Guidance of $3.85-$4.05 vs $4.00 Est

B of A Securities analyst Jean Ann Salisbury maintained a Buy rating on Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) following mixed first-quarter <a href="https://www.benzinga.com/news/buybacks/25/05/45164086/chevron-q1-profit-drops-on-higher-costs-weak-international-margins" target="_blank" rel="noreferrer noopener">earnings reported on Friday</a>.
The oil and gas giant reported revenues&nbsp;and other income of&nbsp;$47.61&nbsp;billion, which missed the consensus of&nbsp;$48.09 billion, while adjusted EPS of $2.18 came <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">in line with the consensus</a>.
The analyst noted that Chevron announced a decrease in its share buyback run rate to $2.5-$3 billion per quarter (from $4-4.75 billion prior) while maintaining <a target="_blank" href="https://chevroncorp.gcs-web.com/static-files/3b7ba281-e370-4a3c-842e-138d8f153f96" rel="noreferrer noopener">its </a>capital expenditure guidance.
She says the adjustment was widely anticipated and aligned with their estimates.
Salisbury writes that mounting concerns surrounding OPEC&#8217;s actions and the potential for a recession have created headwinds for the energy sector, particularly impacting production companies. 
Despite these clear macroeconomic challenges in the oil market, she expects CVX&#8217;s increasing free cash flow generation and strong financial position to make it a relatively appealing investment within this space.
RBC Capital Markets analyst Biraj Borkhataria also reiterated an Outperform rating with a price forecast of $175.
The analyst says CVX&#8217;s results and management commentary suggest a deliberate and prudent approach, a strategy that has historically benefited the company.
He adds that the decision to decrease share repurchases will likely slow the re-leveraging process.
Borkhataria further writes that the company&#8217;s balance sheet retains sufficient strength to sustain its revised, consistent buyback program throughout market cycles.
Investors can gain exposure to CVX via EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and SPDR Select Sector Fund – Energy Select Sector (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>).
Price Action: CVX shares are down 1.48% at $136.45 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45198741/goldman-sachs-issues-bearish-40-oil-forecast-as-opec-pumps-more-energy-stocks-sink" target="_blank" rel="noreferrer noopener">Goldman Sachs Issues Bearish $40 Oil Forecast As OPEC+ Pumps More: Energy Stocks Sink</a></li>
</ul>
Photo: Shutterstock

Equities

Large Cap

Reiteration

DRLL

Analysts Still Like Chevron, Cite Strong FCF & Balance Sheet As Key Amid OPEC And Recession Fears

Each project will provide clean energy to distinct clean energy subscription programs in Sonoma, Mendocino, and Fresno counties

Financing

CASH

Renewable Properties Begins Construction On Three California Projects; Optus Bank Pathward And BridgePeak Energy Capital Provided Two Loans Totaling $16.3M And $19.518M Respectively

KeyBanc Capital Markets analyst Aleksey Yefremov reiterated an Overweight rating on DuPont de Nemours, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) on Sunday and raised the price target from $81.00 to $85.00.
DuPont posted a strong <a href="https://www.benzinga.com/news/earnings/25/05/45170554/dupont-delivers-strong-q1-highlights-electronics-spin-off-confirms-2025-guidance" target="_blank" rel="noreferrer noopener">first-quarter 2025</a> earnings beat, driven by sustained growth in its electronics, water, and healthcare segments. The company reaffirmed its full-year 2025 guidance and confirmed that the planned spin-off of its Electronics business is on track for Nov. 1, 2025.
The analyst noted that DuPont has seen no signs of a broader demand slowdown as of April. Strength in water and healthcare is expected to more than offset continued softness in the automotive and construction markets. As a result, the price target was increased to $85, reflecting enhanced confidence in DuPont&#8217;s growth outlook and more optimistic earnings expectations.
The Electronics segment saw a Q1 boost, partly due to demand pull-forward in China, with full-year growth on track at 6–7% and no slowdown in key drivers like advanced semiconductor nodes and packaging, wrote the analyst.
Related: <a href="https://www.benzinga.com/25/05/45196554/these-analysts-boost-their-forecasts-on-dupont-after-upbeat-results" target="_blank" rel="noreferrer noopener">These Analysts Boost Their Forecasts On DuPont After Upbeat Results</a>
Tariffs had a smaller-than-anticipated impact, estimated at just $0.10 per share for 2025, with potential for further mitigation. After accounting for potential tariff impacts, the analyst forecasts that the underlying EBITDA will be approximately $3.290 billion, with EPS projected at $4.25.
DuPont expects adjusted EPS of $4.30–$4.40, revenue between $12.8 billion and $12.9 billion, and Operating EBITDA of $3.325 billion—$3.375 billion.
The analysts&#8217; estimates for EBITDA and EPS are slightly lower than DuPont&#8217;s guidance due to concerns over weaker construction and auto markets and the potential impact of tariffs.
The analyst also noted that DuPont does not foresee additional risks to Tyvek in China beyond the current investigation. While the investigation is ongoing, sales continue as usual. Tyvek sales in China account for less than 1% of DuPont&#8217;s total sales.
Price Action: DD shares were down 2.8% to $65.37 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45205780/5-sp-500-stocks-that-defy-sell-in-may-myth-with-strong-historical-gains">S&amp;P 500 Stocks That Defy &#8216;Sell In May&#8217; Myth: 5 Companies With Strong Historical Gains</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Price Target

Analyst Ratings

DuPont Analyst Sees Strength In Q1 Results, Electronics Growth, 2025 Outlook

Announced clinical trial collaboration and supply agreement with Johnson &amp; Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations
&nbsp;
Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of registrational trials for both programs in 2026

Biotech

General

ORIC

Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations

Ethan Allen Interiors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.46 by 17.39 percent. This is a 20.83 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $142.69 million which missed the analyst consensus estimate of $146.85 million by 2.83 percent. This is a 2.54 percent decrease over sales of $146.42 million the same period last year.

Ethan Allen Interiors Q3 Adj. EPS $0.38 Misses $0.46 Estimate, Sales $142.69M Miss $146.85M Estimate

ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) raises FY2025 sales outlook from $270.00 million-$280.00 million to $281.00 million-$291.00 million vs $276.42 million estimate.

TDUP

ThredUp Raises FY2025 Sales Guidance from $270.00M-$280.00M to $281.00M-$291.00M vs $276.42M Est

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) affirms FY2025 sales outlook from $610.00 million-$630.00 million to $610.00 million-$630.00 million vs $611.38 million estimate.

Limbach Holdings Affirms FY2025 Sales Guidance of $610.00M-$630.00M vs $611.38M Est

IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) reported quarterly losses of $(2.64) per share which missed the analyst consensus estimate of $(0.93) by 183.87 percent. This is a 617.65 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $570.50 million which missed the analyst consensus estimate of $808.52 million by 29.44 percent. This is a 91.38M percent increase over sales of $624.30 the same period last year.

IAC Q1 EPS $(2.64) Misses $(0.93) Estimate, Sales $570.50M Miss $808.52M Estimate

TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 100 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $44.80 million which beat the analyst consensus estimate of $44.26 million by 1.22 percent. This is a 9.13 percent increase over sales of $41.05 million the same period last year.

TRUE

TrueCar Q1 EPS $(0.12) Beats $(0.13) Estimate, Sales $44.80M Beat $44.26M Estimate

Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.59 by 17.61 percent. This is a 71.56 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $164.07 million which missed the analyst consensus estimate of $444.85 million by 63.12 percent. This is a 52.11 percent increase over sales of $107.87 million the same period last year.

PLMR

Palomar Hldgs Q1 Adj. EPS $1.87 Beats $1.59 Estimate, Sales $164.07M Miss $444.85M Estimate

ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) sees Q2 sales of $72.500 million-$74.500 million vs $71.08 million analyst estimate.

ThredUp Sees Q2 Sales $72.500M-$74.500M vs $71.08M Est

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported quarterly earnings of $1.45 per share which missed the analyst consensus estimate of $1.57 by 7.64 percent. This is a 15.2 percent decrease over earnings of $1.71 per share from the same period last year. The company reported quarterly sales of $1.67 billion which missed the analyst consensus estimate of $1.73 billion by 3.36 percent. This is a 8.05 percent decrease over sales of $1.81 billion the same period last year.

Clorox Q3 Adj. EPS $1.45 Misses $1.57 Estimate, Sales $1.67B Miss $1.73B Estimate

V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) affirms FY2025 Adj EPS guidance from $4.45-$4.85 to $4.45-$4.85 vs $2.67 analyst estimate. Affirms FY2025 sales outlook from $4.38 billion-$4.50 billion to $4.38 billion-$4.50 billion vs $4.47 billion estimate.

V2X Affirms FY2025 Adj EPS Guidance of $4.45-$4.85 vs $2.67 Est; Affirms FY2025 Sales Guidance of $4.38B-$4.50B vs $4.47B Est

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.33 by 6.77 percent. This is a 17.36 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $337.71 million which missed the analyst consensus estimate of $339.88 million by 0.64 percent. This is a 20.29 percent increase over sales of $280.75 million the same period last year.

Comments

Mirum Pharmaceuticals

Mirum Pharmaceuticals (MIRM) Opzioni

Mirum Pharmaceuticals (NASDAQ:MIRM) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO